Search Bar & Filters
Found 21 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating a blood-based test called Episwitch CiRT4 to see if it can predict how patients with stage III or IV cancer will respond to immune checkpoint inhibitor ICI treatments, specifically PD-L-1 inhibitors. This observational study aims to compare test predictions with actual patient responses across different types of cancer. The study also explores how social factors might relate to treatment responses and outcomes. Patients who are candidates for or currently receiving ICI therapy will undergo the Episwitch CiRT4 test before starting or during treatment. If the test indicates a high likelihood of response, repeat testing will occur every three months. Participants will be followed for six months to collect data on treatment administered, disease progression, survival, and patient-reported outcomes, along with social determinants of health. Throughout the study, researchers will gather clinical information, including physician questionnaires and patient feedback, to assess outcomes such as disease-free survival and time to recurrence. The study will also analyze health economics related to the tests potential to reduce unnecessary ICI treatments. Monitoring will continue for 24 weeks, with comprehensive data collection to evaluate the correlation between test results, social factors, and patient outcomes.
Actively Recruiting
Researchers are evaluating treatments for patients with hormone receptor-positive, HER2-negative, PIK3CA-mutated breast cancer that is locally advanced or metastatic. This phase III, global, randomized, open-label study compares the effectiveness and safety of inavolisib combined with fulvestrant versus alpelisib combined with fulvestrant. Participants have experienced disease progression during or after therapy with cyclin dependent kinase 46 inhibitors combined with endocrine therapy. Participants receive study drugs in repeated 28-day cycles. Inavolisib is taken orally once daily at 9 mg on days 1 to 28 of each cycle, while fulvestrant is administered at 500 mg on days 1 and 15 of the first cycle and day 1 of subsequent cycles. The comparator group receives alpelisib at 300 mg orally once daily plus fulvestrant on the same schedule. A substudy evaluates the effect of inavolisib plus fulvestrant on the metabolism of certain enzyme substrates by administering midazolam, omeprazole, and bupropion on specified days within the first cycle. Participants undergo regular assessments including tumor evaluations per RECIST criteria, blood tests, and monitoring of drug levels. The primary outcome measures progression-free survival assessed by independent review up to approximately 64 months. Secondary outcomes include overall survival, response rates, quality of life, and safety events monitored up to about 85 months. The study includes frequent visits during treatment cycles and follow-ups to evaluate side effects and long-term outcomes.
Actively Recruiting
Researchers are evaluating the safety and effectiveness of targeted therapies and immunotherapy, either alone or in combination, for patients with metastatic colorectal cancer mCRC whose tumors test positive for specific biomarkers. This open-label, Phase 11b study enrolls participants into different treatment groups based on their biomarker test results to explore personalized treatment approaches. Participants receive various combinations of study drugs, including oral medications like inavolisib and divarasib and intravenous infusions such as cetuximab, bevacizumab, atezolizumab, tiragolumab, SY-5609, FOLFOX, and FOLFIRI chemotherapy. Treatment cycles vary from 21 to 28 days depending on the assigned treatment arm, with dosing schedules including daily oral medications and infusions given weekly, every two weeks, or every three weeks. Some treatment arms are closed or not recruiting, while others remain active. Throughout the study, participants undergo regular assessments including tumor imaging to measure response, blood tests, and biomarker sampling. Researchers monitor outcomes such as objective response rate, disease control, duration of response, and adverse events over approximately 84 months. Participants overall health and tumor status are closely followed to evaluate treatment effects and safety during and after therapy.
Actively Recruiting
The trial investigates treatments for adults with KRASNRAS and BRAF wild-type recurrent, unresectable, or metastatic colorectal cancer who have previously undergone chemotherapy. It compares how long participants live without disease progression and overall survival when treated with two different combinations of chemotherapy and targeted biological agents. This phase 3 study explores differences in outcomes between the use of amivantamab plus FOLFIRI chemotherapy and cetuximab or bevacizumab plus FOLFIRI chemotherapy. Participants are randomly assigned to one of two groups. One group receives amivantamab together with FOLFIRI, a chemotherapy regimen including 5-fluorouracil, leucovorin calcium or levoleucovorin, and irinotecan. The other group receives either cetuximab or bevacizumab with the same FOLFIRI chemotherapy. Treatments are given in 28-day cycles and continue until disease progression is observed on scans or other stopping criteria are met. During the study, participants undergo regular monitoring including radiographic scans to assess disease status and progression-free survival for up to 2 years and overall survival for over 4 years. Researchers also evaluate tumor response rates, duration and time to response, quality of life through questionnaires, side effects, and laboratory tests. The total study duration may extend up to more than 4 years to thoroughly assess treatment outcomes and safety.
Actively Recruiting
Researchers are evaluating nemtabrutinib compared with the investigators choice of ibrutinib or acalabrutinib in adults with untreated chronic lymphocytic leukemia CLL or small lymphocytic lymphoma SLL. The study aims to determine if nemtabrutinib is not less effective than these treatments in producing an objective response and whether it can improve progression-free survival. This is a Phase 3, randomized trial sponsored by Merck Sharp & Dohme LLC. Participants will be randomly assigned to receive either nemtabrutinib or one of the comparator drugs, ibrutinib or acalabrutinib, all administered orally. Treatment will continue until disease progression, unacceptable side effects, or other reasons for stopping treatment occur. The study compares these treatment options directly to assess their effects on the disease. Throughout the trial, participants will undergo evaluations including tumor response assessments according to established criteria, progression tracking, and safety monitoring for adverse events. These assessments will continue for up to approximately 44 months for the primary response and up to 104 months for progression-free survival and other long-term outcomes. The study involves regular visits and ongoing monitoring to understand how participants respond to the treatments over time.
Actively Recruiting
Researchers are investigating whether adding intismeran autogene to pembrolizumab after surgery helps prevent cancer from returning in people with non-small cell lung cancer NSCLC whose tumors did not fully respond to treatment before surgery. This randomized phase 3 clinical trial compares pembrolizumab combined with intismeran autogene versus pembrolizumab with placebo in participants with resectable Stage II to IIIB NSCLC. The study focuses on individuals who have not achieved a complete pathological response after neoadjuvant therapy, aiming to improve disease-free survival. Participants receive neoadjuvant treatment consisting of pembrolizumab via intravenous infusion every 3 weeks for up to 4 cycles, combined with background chemotherapy chosen by the investigator. After surgery, the adjuvant treatment phase involves pembrolizumab given intravenously every 6 weeks for up to 7 cycles, plus either intismeran autogene or placebo administered by intramuscular injection every 3 weeks for up to 9 doses. The neoadjuvant phase lasts about 12 weeks, and the adjuvant phase extends up to approximately 42 weeks. During the study, participants will have regular assessments including monitoring for disease recurrence, survival, and quality of life using standardized questionnaires. Researchers will track adverse events and treatment tolerability throughout the trial, with follow-up lasting up to over 8 years to evaluate long-term outcomes. The main measurement is disease-free survival, with additional evaluations of overall survival, distant metastasis-free survival, and lung cancer-specific survival, along with patient-reported quality of life and safety data.
Actively Recruiting
Researchers are evaluating treatments for adults with multiple myeloma, a type of blood cancer that has returned or is not responding to current therapies. This Phase 2 study focuses on the drug belantamab mafodotin given less frequently alongside standard cancer medicines to see if it can effectively control the disease while reducing side effects, especially those affecting the eyes. The study also monitors overall treatment response and safety. Participants receive belantamab mafodotin combined with one of three standard regimens pomalidomide plus dexamethasone, bortezomib plus dexamethasone, or carfilzomib plus dexamethasone. The drug dosing is extended to potentially reduce side effects. The study is open-label and non-randomized, with each participant assigned to one of these three treatment combinations. During the study, participants undergo regular assessments including eye exams, tests to measure cancer response, and monitoring for side effects. The main outcome measured is the overall response rate up to about 52 months. Secondary measures include complete response rate, minimal residual disease negativity, duration of response, and detailed safety monitoring including eye-related symptoms. The study lasts until August 2030, with ongoing safety and effectiveness evaluations throughout.
Actively Recruiting
Researchers are comparing the effectiveness and safety of sonrotoclax combined with either obinutuzumab or rituximab against venetoclax combined with rituximab in adults with relapsed or refractory chronic lymphocytic leukemia CLL or small lymphocytic lymphoma SLL. This phase 3 study aims to assess progression-free survival and other important outcomes among these treatment combinations to find better options for patients. Participants will be randomly assigned to one of four treatment groups sonrotoclax plus obinutuzumab, sonrotoclax plus rituximab, sonrotoclax plus obinutuzumab guided by minimal residual disease evaluation, or venetoclax plus rituximab. Sonrotoclax and venetoclax are given orally, while obinutuzumab and rituximab are given intravenously. The study includes detailed treatment schedules and monitoring of minimal residual disease in one group. During the study, participants will have regular evaluations including assessments by blinded independent review committees of progression-free survival, response rates, and overall survival. Quality of life and symptom burden will also be measured using specific questionnaires. Safety will be monitored from the first dose through follow-up periods lasting up to several years. The total study duration extends to approximately six years, with ongoing assessments to understand treatment effects and safety.
Actively Recruiting
Researchers are evaluating the effectiveness of the Change4Better C4B mobile app in reducing the severity of problem gambling compared to standard treatment as usual TAU. This study is a 6-month randomized clinical trial involving individuals with gambling disorder who are enrolled in or seeking treatment at outpatient facilities affiliated with Bettor Choice Gambling Treatment Programs or Kindbridge Behavioral Health. The study aims to assess the feasibility and efficacy of adding the C4B app, which is based on cognitive behavioral therapy, as a support tool alongside routine outpatient treatment. Participants will be randomly assigned to one of two groups one group will receive standard TAU, which includes individual or group therapy sessions tailored to their needs and usually lasts about one hour per week for 12 weeks. The other group will receive TAU plus access to the C4B mobile app, which teaches skills to manage gambling behaviors and cognitive distortions. Participants using the app will be instructed by staff on how to use it and encouraged to spend about 8 hours over 12 weeks completing modules and practicing exercises. Monthly follow-up continues for an additional 12 weeks, during which the app remains accessible. During the study, participants will be monitored for changes in gambling symptom severity from baseline to 6 months. Researchers will track app engagement through measures such as days used, topics completed, practice exercises, weekly usage, and total time spent. Participants will continue receiving usual outpatient care, and data will be collected through assessments and follow-ups conducted by the Yale research team. The total study duration for each participant is 6 months, starting from randomization.
Actively Recruiting
Researchers are studying patients with non-small cell lung cancer NSCLC to better understand how the cancer changes on a molecular level during standard treatments. The study aims to track the diseases progress and explore how changes in circulating tumor DNA ctDNA might predict cancer recurrence and treatment outcomes. This observational study collects clinical and molecular health data over time from patients receiving usual care. The study involves two groups of patients. The first group includes patients with early-stage NSCLC Stages I to IIIB who are treated with surgery and possibly additional therapies before or after surgery. The second group includes patients with advanced stage IV NSCLC receiving first-line immunotherapy, either alone or combined with chemotherapy. Patients will provide blood samples regularly during their routine care to help researchers analyze ctDNA and its changes over time. Participants will be asked to provide tumor samples and give additional blood samples during standard surveillance visits. Researchers will monitor disease-free survival and overall survival over periods up to five years. They will also compare ctDNA testing results with traditional imaging methods used every six months to detect cancer recurrence. The study tracks various outcomes, including treatment patterns and progression-free survival, to gain a detailed understanding of how the disease evolves under standard care.
1-10 of 21
1